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S Lemler1, J Hayden3, RM Krauss4, Z Desta1, DA Flockhart1 and DF Hayes3 for The Consortium on
Breast Cancer Pharmacogenomics (COBRA)
Tamoxifen induces important changes in serum lipid profiles in some women; however, little information is available to
predict which women will experience improved lipid profiles during tamoxifen therapy. As part of a multicenter
prospective observational trial in 176 breast cancer patients, we tested the hypothesis that tamoxifen-induced lipid
changes were associated with genetic variants in candidate target genes (CYP2D6, ESR1, and ESR2). Tamoxifen lowered
low-density lipoprotein cholesterol (Po0.0001) by 23.5mg/dl (13.5–33.5mg/dl) and increased triglycerides (P¼ 0.006). In
postmenopausal women, the ESR1-XbaI and ESR2-02 genotypes were associated with tamoxifen-induced changes in
total cholesterol (P¼ 0.03; GG vs GA/AA) and triglycerides (P¼ 0.01; gene–dose effect), respectively. In premenopausal
women, the ESR1-XbaI genotypes were associated with tamoxifen-induced changes in triglycerides (P¼ 0.002;
gene–dose effect) and high-density lipoprotein (P¼ 0.004; gene–dose effect). Our results suggest that estrogen receptor
genotyping may be useful in predicting which women would benefit more from tamoxifen.
The use of exogenous estrogen to prevent cardiovascular
disease in women has been a subject of controversy since data
from the Women’s Health Initiative trial suggested that
postmenopausal women might experience a greater number
of cardiovascular events when treated with hormone
replacement therapy.1 There is large interindividual varia-
bility in the response to estrogens, and Herrington et al.2 have
suggested that this may be due in part to genetic variants in
the estrogen receptors (ERs). As the Women’s Health
Initiative study made prospective study of the effects of
estrogens difficult and as the selective estrogen response
modifier tamoxifen acts as an exogenous estrogen on serum
lipids, we elected to study the effects of tamoxifen on serum
lipids and to test the hypothesis that genetic variants are
associated with variability in response.
Tamoxifen is a selective ER modulator widely used in the
treatment of ER- or progesterone receptor-positive breast
cancer, and it is the only agent approved for the prevention of
the disease.3–6 As a selective ER modulator, tamoxifen has
both estrogenic and anti-estrogenic effects depending on the
target tissue. Tamoxifen effects on serum lipid concentration
are largely similar to those of estrogen.7,8
Tamoxifen is documented to cause a reduction in serum
total and low-density lipoprotein (LDL), but data on high-
density lipoprotein (HDL) and triglycerides have not been
consistent.9–14 The effects of tamoxifen vary from patient to
patient, and this variability is specifically seen in the response
of lipid parameters.11,14,15 The causes of this variability are
not completely understood, but may be, in part, due to
inherited genetic differences in the cellular receptors.16
Tamoxifen acts via binding and modulation of the ERs,
which are members of the nuclear steroid receptor super-
family. Two subsets of human ERs have been identified: ER-a
and ER-b. These receptors are products of different genes,
designated ESR1 and ESR2, respectively.17–19 The expression
of these receptors is influenced by genetic polymorphisms, as
is the case for other members of the nuclear receptor
superfamily.16 Single-nucleotide polymorphisms (SNPs) in
the genes coding for the ERs may therefore explain some of
the variability seen in the response to tamoxifen, including
changes in lipid profile. The interaction of the ERs with each
other may also be important, as studies have suggested that
ER-b modulates some of the responses resulting from
activation of ER-a targets.20
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Herrington et al.2 have showed an association between
HDL-cholesterol levels and polymorphisms in ER-a gene
related to exogenous estrogen. They reported a significantly
higher HDL response to estrogen therapy compared with
placebo of postmenopausal women who carry the ER-a IVIS-
401C/C genotype vs variant genotypes. Similarly, other
investigators have reported an association between ER genotype
and baseline concentration of LDL-cholesterol in Japanese
school children, who were not exposed to any medications.21
In 2000, we initiated a prospective, multi-institutional cohort
clinical trial to study SNPs in multiple candidate genes and non-
tumoral effects of tamoxifen in women at high risk for or with
newly diagnosed breast cancer. From this cohort, we have
reported previously an association of cytochrome P450 2D6
(CYP2D6) genotypes and tamoxifen metabolite concentrations
in breast cancer patients treated with tamoxifen.22–24 Endoxifen,
an active metabolite of tamoxifen, is 30- to 100-fold more
potent than tamoxifen as an anti-estrogen in the suppression of
estrogen-responsive genes and cell proliferation.22 CYP2D6
genotypes may therefore be associated with non-tumoral
responses of tamoxifen such as lipid profile change.
We report here the results of the analysis of this
prospective cohort in which we tested the hypothesis that
lipid profile changes in breast cancer patients on tamoxifen
therapy are associated with candidate polymorphisms in
ER-a, ER-b, or CYP2D6.
RESULTS
Subjects
The baseline characteristics of the 176 subjects who qualified for
the lipid substudy overall, and the 134 subjects used for the
genotype–phenotype analyses are shown in Table 1 . Our cohort
was composed mostly of Caucasian women (92%). As dictated
by the protocol, the use of lipid-altering medication was no
different at baseline compared with 4 months after initiation
of tamoxifen treatment. Among the 134 samples analyzed for
genotype–phenotype association, seven were African Americans,
one Arabic, one Hispanic, and one Asian (Ta ble 1 ). Their lipids
were not different from the Caucasian lipid samples.
Lipid concentrations independent of genotypes
In the analysis of the primary cohort of 176 women
(N¼ 176) for the lipid substudy, the mean baseline total
cholesterol was lower in premenopausal women compared
with postmenopausal women (211 vs 225mg/dl, P¼ 0.02).
There was a statistically nonsignificant trend toward lower
mean baseline LDL in the premenopausal group compared
with the postmenopausal group (122 vs 135mg/dl, P¼ 0.09).
The mean triglyceride concentration was also lower (124 vs
159mg/dl, P¼ 0.09) and HDL-cholesterol was higher in the
premenopausal group (65 vs 60mg/dl, P¼ 0.03) compared
with their postmenopausal counterparts.
After 4 months of tamoxifen treatment, there was a mean
decrease in () 17.7mg/dl (Pp0.0001) and () 23.5mg/dl
(Pp0.0001) in serum total and LDL-cholesterol concentra-
tion, respectively (Table 2). The triglyceride concentration
increased by a mean of (þ ) 24.4mg/dl (P ¼ 0.006), but the
HDL was not significantly changed compared with baseline
(P ¼ 0.54, Table 2 ). Overall, our data show a shift of the LDL
distribution toward lower concentrations after 4 months of
tamoxifen (Figure 1).
With regard to menopausal status, there was a decrease in
total cholesterol of () 12mg/dl (P ¼ 0.004) and ()
24.1mg/dl (Pp0.0001) for pre- and postmenopausal women,
respectively. When analyzed by menopausal status, the
triglyceride changed by (þ ) 41.3mg/dl (P¼ 0.009) and
(þ ) 17.4mg/dl (P¼ 0.14) in pre- and postmenopausal
women, respectively, compared with baseline. The mean
triglyceride concentration in the premenopausal group had
a trend toward lower values compared with the postmeno-
pausal group (P ¼ 0.09, Table 2).
With regard to the tamoxifen metabolite concentrations,
there was no association between the lipid concentrations
and the metabolite concentrations in the cohort of women
(n¼ 134) who were not on any antilipidemic drugs.
Lipid concentrations and genotypes
As described in Methods, 134 women who were not
taking lipid-lowering medications and in whom menstrual
Table 1 Baseline characteristics of patients in study
Entire cohort Genotype–phenotype cohort
Characteristics (N=176) (N=134)a
Age (years), mean (range) 55 (32–82) 50 (33–78)
Premenopausal 49 (32–63) 48 (34–63)
Perimenopausal 53 (45–60) 63 (39–80)
Postmenopausal 64 (39–82)
BMI, mean (SD) 27 (8) 27 (6)
Race/ethnicityb
African Americans 8 (4)c 7 (5)
Caucasians 161 (92) 125 (93)
Othersc 7 (4) 3 (2)
Menopausal statusb
Premenopausal 55 (31) 53 (39)
Perimenopausal 20 (11) 0 (0)
Postmenopausal 101 (57) 81 (61)
Patients on lipid-lowering medicationsb
At baseline 22 0
At 4 months 22 0
BMI, base metabolic index; N, number in each category. aGenotype–phenotype
cohort refers to the 136 patients for the genotype–lipid association analysis who
were neither perimenopausal nor on lipid-lowering medications. bNumber in group
(%). cOthers consist of two patients of Arabic, one of Hispanic, one of Asian, and two
of unknown ancestry, and race/ethnicity percentages may not add up to 100
because of rounding.
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status was clear were included in the genotype–phenotype
analysis.
Serum lipid concentrations and ER-a PvuII genotypes. Asso-
ciations between polymorphisms in ER-a and serum lipid
concentrations were analyzed. For ER-a PvuII, there were no
obvious or statistically significant associations between
polymorphisms and any of the lipid concentrations, either
at baseline or after 4 months of tamoxifen (data not shown).
Serum lipid concentrations and ER-a XbaI genotypes. At
baseline, serum triglyceride and HDL-cholesterol concentra-
tions were similar regardless of ER-a XbaI genotype, but the
mean total and LDL-cholesterol concentrations differed
according to ER-a XbaI polymorphism (Table 3a). The mean
baseline total serum cholesterol concentrations were 223, 214,
and 244mg/dl for the AA, AG, and GG genotypes of ER-a
XbaI, respectively (P¼ 0.017 for comparison of GG vs AA/
AG), and mean LDL-cholesterol levels were 135, 125, and
150mg/dl, for the three genotypes, respectively (P¼ 0.03). In
subset analyses according to menstrual status, these differ-
ences remained statistically significant for premenopausal, but
not postmenopausal women (Table 3a). Although there were
trends toward an association between this ESR1 variant and
effects on lipids in postmenopausal that are consistent with
the work of Herrington et al.2 and others when hormone
replacement therapy was studied, these did not reach
statistical significance. Premenopausal women who carried
the GG genotype had a mean baseline serum cholesterol
concentration of 244mg/dl compared with 206mg/dl in
women with the AA/AG alleles (P ¼ 0.04), and mean LDL-
cholesterol levels of 148mg/dl for GG compared with 120 and
118mg/dl for AA and AG, respectively (P ¼ 0.04, Table 3a).
Following 4 months of tamoxifen treatment, we observed
a statistically significant association between the change in
total cholesterol and ER-a Xba I in postmenopausal (Table
3b ) but not premenopausal women (Table 3b and Figure
2a ). The changes in total cholesterol concentration were ()
22mg/dl, () 20mg/dl, and () 40mg/dl for the AA, AG,
and GG genotypes in ER-a XbaI, respectively, with a
statistically significant difference for the AA/AG versus GG
genotypes (P ¼ 0.03, Table 3b ). Although, as shown in
Table 2, total serum cholesterol decreased with tamoxifen
in premenopausal women (P¼ 0.004), no obvious or
statistically significant tamoxifen-induced changes in total
cholesterol were observed according to ER-a XbaI genotype
in this menstrual subgroup (Figure 2a ).
In contrast to the results seen with total cholesterol, no
statistically significant association between ER-a XbaI and
tamoxifen-induced changes in triglycerides, LDL- or HDL-
cholesterol were observed in postmenopausal women ( Table 3b).
However, in premenopausal women, tamoxifen treatment was
associated with a statistically significant correlation between
ER-a XbaI polymorphism and changes in triglycerides and HDL
concentrations (P ¼ 0.004, Figure 2 ). There was a mean
change in triglyceride of () 7mg/dl, (þ ) 46mg/dl, and (þ )
163mg/dl for women who carry the AA, AG, and GG genotypes,
respectively ( P ¼ 0.002 for gene–dose effect, Figure 2b ).
Similarly, the change in serum HDL-cholesterol was observed
to be associated with the ER- a XbaI polymorphism ( Figure 2c ).
HDL concentration changed by (þ ) 5mg/dl, () 0.6mg/dl,
and () 4mg/dl for the AA, AG, and GG genotypes, respectively
(P¼ 0.004 for gene–dose effect).
Serum lipid levels and ER-b genotypes. In postmenopausal
women, changes in triglyceride levels, but not total, HDL-, or
LDL-cholesterol levels, were associated with ER-b (ESR2-02
Table 2 Change in lipid concentrations after 4 months of tamoxifen treatment
All subjects (N=176) Premenopausal (N=55) Postmenopausal (N=101)
Lipid particle Mean change (95% CI)a P-valueb Mean change (95% CI) P-value Mean change (95% CI) P-value
T-Chol 17.7 (24.7, 10.7) o0.0001 12.0 (20, 4) 0.004 24.1 (30, 18) o0.0001
TG 24.4 (4.4, 44.4) 0.006 41.3 (11.2, 71.5) 0.009 17.4 (4.6, 39.4) 0.14
HDL 0.5 (0.5, 1.5) 0.54 0.7 (2.1, 3.5) 0.60 0.01 (2.0, 2.0) 0.99
LDL 23.5 (13.5, 33.5) o0.0001 18.7 (26.3, 11.1) o0.0001 26.5 (31.1, 20.9) o0.0001
CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; T-Chol, total cholesterol; TG, triglycerides. aMean change in lipid particle concentration is
shown in mg/dl with 95% CI given in parentheses. bP-values are calculated for difference between baseline and lipid concentrations following 4 months of tamoxifen
treatment.
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Figure 1 The distribution of serum cholesterol at baseline and after 4
months of tamoxifen. The plot shows the distribution of serum LDL-
cholesterol at baseline and after 4 months of tamoxifen treatment in 176
breast cancer patients. The baseline distribution is shown in gray bars,
whereas the black bar represents the distribution following 4 months of
tamoxifen treatment. The percentage of patients is on the y axis and LDL
concentration (mg/dl) is shown on the x axis. The LDL categories were
selected arbitrarily and no test statistics were conducted.
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rs498693) genotypes (Figu re 3). After 4 months of tamoxifen
in these subjects, triglyceride levels were (þ ) 71mg/dl, (þ )
8mg/dl, and () 15mg/dl from baseline for the GG, AG, and
AA genotypes in ESR2-02, respectively (P ¼ 0.01 for gene–-
dose effect,  Figure 3b ). Although postmenopausal women
had a mean change in HDL-cholesterol of () 1.2mg/dl, ()
1.4mg/dl, and (þ ) 4mg/dl for the, GG, AG, and AA
genotypes, respectively, the difference was not statistically
significant (P ¼ 0.23 for gene–dose effect, Figure 3c ). Like-
wise, changes in total cholesterol and LDL-cholesterol were
not statistically significantly associated with ER- b genotype
(Figure 3a and d).
Table 3a Mean baseline lipid concentrations according to ER- XbaI genotype and menopausal status
ER- XbaI genotype Lipid particle AA (n=50) AG (n=59) GG (n=19) P-valuea
All women (N=128)b Total cholesterol 223 (215, 231)c 214 (206, 222) 244 (228, 260) 0.017
Triglycerides 131 (109, 153) 132 (110, 154) 142 (102, 182) 0.63
HDL-cholesterol 61 (57, 65) 63 (59, 67) 65 (57, 73) 0.49
LDL-cholesterol 135 (128, 142) 125 (117, 133) 150 (136, 164) 0.03
Premenopausal women (N=53) Total cholesterol 206 (184, 229) 206 (192, 220) 244 (212, 276) 0.04
Triglycerides 119 (67, 171) 113 (83, 157) 142 (66, 218) 0.53
HDL-cholesterol 61 (54, 70) 66 (59, 71) 67 (55, 79) 0.61
LDL-cholesterol 120 (101, 137) 118 (105, 129) 148 (122, 174) 0.04
Postmenopausal women (N=81) Total cholesterol 230 (218, 242) 222 (208, 236) 243 (221, 265) 0.16
Triglycerides 135 (112, 160) 152 (124, 180) 142 (100, 184) 0.94
HDL-cholesterol 61 (57, 65) 60 (54, 66) 64 (54, 74) 0.54
LDL-cholesterol 141 (131, 151) 131 (119, 143) 151 (131, 171) 0.20
CI, confidence interval; ER-a, estrogen receptor alpha; HDL, high-density lipoprotein; LDL, low-density lipoprotein. aP-values are calculated for the differences between the AA/
AG and the GG alleles. bNumber of ER-a genotypes available. cMean baseline lipid particle concentration (95% CI).
Table 3b Association of total cholesterol concentration change at 4 months with ER- XbaI genotypes (postmenopausal group)
ER- XbaI genotype
Lipid particle AA (n=36) AG (n=29) GG (n=12) P-valuea
Total cholesterol 22 (30, 14)b 20 (30, 10) 40 (58, 22) 0.03
Triglycerides 17 (19, 53) 33 (9, 74) 29 (35, 93) 0.07
HDL-cholesterol 0 (3.4, 3.4) 1.3 (2.7, 5.3) 1.2 (7.2, 4.8) 0.19
LDL-cholesterol 25 (33, 17) 23 (33, 13) 40 (56, 24) 0.08
CI, confidence interval; ER-a, estrogen receptor alpha; HDL, high-density lipoprotein; LDL, low-density lipoprotein. aP-values are calculated for the differences between
baseline and 4 months concentration for the AA/AG vs the GG alleles. bChange in serum lipid particle concentration is shown in mg/dl with 95% CI.
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Figure 2 Response of serum lipid particle to tamoxifen in premenopausal women according to ER-a XbaI genotype. (a) Total cholesterol, (b) triglycerides, (c)
HDL-cholesterol, and (d) LDL-cholesterol. The bars show the mean change in serum lipid concentration (mg/dl), whereas the error bars are the SE of the
means. The y axis indicates the direction of the change in lipid concentration. The number of subjects in each genotype group is in parentheses against each
bar. *P-value for gene–dose effect.
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In premenopausal women, the change in triglyceride was
(þ ) 97mg/dl, (þ ) 37mg/dl, and (þ ) 7mg/dl for the GG,
AG, and AA genotypes in ESR2-02, respectively (P¼ 0.04 for
gene–dose effect; data not shown). No other association
between ER-b polymorphisms and lipid level changes was
detected in these younger subjects (data not shown).
Serum lipid concentration and CYP2D6 genotypes. We have
reported previously that tamoxifen is metabolized to a highly
abundant, potent anti-estrogenic metabolite, endoxifen
(4-hydroxy-N-desmethyl-tamoxifen) by CYP2D6.24 Endox-
ifen concentrations are lowered by genetic variants in
CYP2D6 and by pharmacologic inhibitors of CYP2D6.24 A
recently published report suggests that breast cancer patients
treated with adjuvant tamoxifen who carry the *4 genotype of
CYP2D6 have poorer outcomes than those with wild-type
CYP2D6.25 However, we did not observe a statistically
significant association between CYP2D6 genotype and the
change in lipid particle concentration in response to
tamoxifen treatment (data not shown).
Tamoxifen and LDL subfractions
LDL consists of heterogenous particles and small, dense LDL
particles are regarded as an independent risk factor for
coronary artery disease.26 A small non-human primate study
has suggested that tamoxifen may adversely affect LDL
particles.27 In a preliminary subset of 50 patients, we
explored the effects of tamoxifen on LDL subfraction
diameter and composition, but none were observed (data
not shown). The mean LDL subfraction diameter at baseline
was 268.0 A˚ compared with 266.8 A˚ after 4 months of tam-
oxifen treatment (P¼ 0.47). These data are consistent with
published data indicating no change in small, dense LDL
particle after treatment with hormone replacement therapies.
Power analysis
With 176 subjects, we have 99% power to detect the observed
decreases (Table 2 ) in total cholesterol and LDL, and 91%
power to detect the observed increase in triglycerides with 5%
type I error. The power calculation was based on an empirical
t-test distribution from a repeated measure two-way analysis
of variance (ANOVA) model (see Methods).
When subjects who were taking lipid-altering medications
or whose menopausal status was unclear were excluded, 134
subjects remained. On the basis of the observed effect size
(Table 3a ), we have 87% power to detect the effect of ER- a
XbaI on the total cholesterol, and 71% power to detect its
effect on the LDL. The type I error was justified by multiple
SNPs in an empirical t-test distribution from a two-way
ANOVA model (see Methods).
Using these 134 samples, based on the observed effect size
(Figures 2 and 3), we have 74 and 70% power to detect
the effect of ER-a XbaI on the triglycerides and HDL,
respectively, among premenopausal women, and we have
65% power to detect ESR2-02 effects on the triglycerides. The
type I error was justified by multiple SNPs and menopause
groups in an empirical t-test distribution from a two-way
ANOVA model (see Methods).
According to data from the 50 subjects, we were able to
analyze for more specific lipid subfractions. The maximum
effect size of any possible genotype on the change in
subfraction distribution after 4 months of tamoxifen
treatment did not exceed 0.15, where the effect size is defined
as the change in lipid concentration brought about by
tamoxifen, divided by its SD. It follows that none of these
changes are consistent or large enough to be clinically
meaningful and that a study of more than 2,000 patients
would be required to detect a change with 80% power.
DISCUSSION
In this prospective study, we observed that serum
lipid concentrations in women at baseline and after
taking tamoxifen for the treatment of breast cancer were
associated with germline ER genotypes and presumably with
the estrogen agonistic effects of tamoxifen on the ERs.
Overall, the response of serum lipid concentrations to
tamoxifen in our cohort was consistent with data reported
previously.9,28
(m
g/d
l)
–35
–30
–25
–20
–15
–10
–5
0
GG(28) AG(37) AA(11)
P=0.36
(m
g/d
l)
–60
–40
–20
0
20
40
60
80
100
GG(28)
∗
 AG(37) AA(11)
P=0.01
(m
g/d
l)
–4
–2
0
2
4
6
8 GG(28) AG(37) AA(11)
P=0.23
(m
g/d
l)
–40
–30
–20
–10
0
GG(28) AG(37) AA(11)
P=0.10
a b
c d
Figure 3 Response of lipid concentration to tamoxifen in postmenopausal women according to ER-b (ESR2-02) polymorphism. (a) Total cholesterol, (b)
triglycerides, (c) HDL-cholesterol, and (d) LDL-cholesterol. The bars show the mean change in serum lipid concentration (mg/dl), whereas the error bars are
the SE of the means. The y axis indicates the direction and magnitude of the change in serum lipid concentration. The number of subjects in each genotype
group is in parentheses against each bar. *P-value for gene–dose effect.
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Tamoxifen treatment was associated with significant
reductions in both total and LDL-cholesterol but, unlike
exogenous estrogen, with no change in HDL-cholesterol.
Conversely, triglyceride concentration increased significantly
when compared with baseline. A greater reduction in serum
total cholesterol concentration after 4 months of tamoxifen
was observed in postmenopausal women when compared
with premenopausal women, but this difference did not
achieve statistical significance (P¼ 0.06). The association
observed between ER genotypes and the response of serum
lipid particle concentrations was different in premenopausal
women compared with the postmenopausal group. In
postmenopausal women, we observed a significant association
between ER-a XbaI and the change in total cholesterol in
response to tamoxifen treatment. Although this association
was not seen with premenopausal women, the baseline total
cholesterol concentration was found to be lower in women
with the AA/AG compared with GG genotypes of the ER-a
XbaI polymorphism. Similarly, a previous study reported an
association between ER-a XbaI and the serum cholesterol
concentration in Japanese school-age children.21 These
differences in the experiences of pre- and postmenopausal
women with regard to baseline cholesterol and the response to
tamoxifen treatment lead us to speculate that the association
may be related to the higher concentrations of estrogen in
premenopausal compared with postmenopausal women.
The differences seen with regard to menopausal status and
ER genotypes were particularly evident in the case of serum
triglycerides. We observed a group of women who had a
reduction in serum triglyceride concentration in response to
tamoxifen. Postmenopausal women with the AA genotype of
ER-b (ESR2-02) had a mean reduction of () 15mg/dl in
triglyceride concentration compared with an increase of
71mg/dl in women with the GG genotype. In premenopausal
women, although there was no reduction in the mean
triglyceride concentration in women with the AA genotype of
ESR2-02, there was an increase of only 7mg/dl compared
with 97mg/dl in women with the GG genotype. It is possible
that endogenous circulating and tissue concentrations of
estrogen in premenopausal women would dampen the
agonistic effects of tamoxifen and its metabolites, whereas
these effects would be more evident in the setting of lower
estrogen concentrations in postmenopausal women. In both
groups of women, the change in HDL-cholesterol was in a
direction that was predictable based on changes seen in the
serum triglycerides. These genetic associations are biologi-
cally plausible, as the changes in serum triglycerides and HDL
seen with specific ER variants are in a consistent direction.
Although hormone replacement therapy and exogenous
estrogen have been shown to alter the serum concentrations
of HDL, this has never been reported with tamoxifen. It
follows that although the mechanism of action of tamoxifen
is similar and probably mediated through at least ERa, there
are also subtle differences between its action and that of
estrogen itself. In this study, hints of these differences are also
present. These may reflect the activity of different estrogenic
and anti-estrogenic metabolites. Consistent with an estro-
genic effect, GG XbaI genotype was associated with a greater
lowering of total cholesterol and a greater increase in
triglycerides on tamoxifen therapy. In contrast, there was a
trend toward greater reduction in HDL levels, presumably
through another mechanism.
Although we have previously reported the effect of
CYP2D6 genotype on endoxifen concentration,24 no associa-
tion was detected between this genotype and lipid particle
concentration. This observation suggests that endoxifen,
being anti-estrogenic, may not play a role in the effects of
tamoxifen or its other metabolites on the observed changes in
lipid concentrations.
Previous studies of the association between genetic
variation in ER-a and serum lipid concentrations have
yielded inconsistent data. For instance, Herrington et al.2
have shown an association between ER-a PvuII and the
response of serum HDL-cholesterol to estrogen therapy. After
annual follow-up for 3.2 years, they observed that women
with the CC genotype had a significantly greater increase in
HDL-cholesterol in response to estrogen therapy compared
with the CT/TT genotypes. However, Almeida et al.29 did not
observe a similar association in postmenopausal women on
estrogen therapy after 4 months of treatment. Although we
detected associations between ER-a XbaI polymorphisms and
tamoxifen-induced lipid changes, we observed none with
ER-a PvuII.
Almeida et al.30 have recently reported an association
between ER-b and the response of serum lipids in 472 women
unexposed or exposed to estrogen therapy for at least 4
months. They found that LDL-cholesterol concentrations
were associated with ER-b 1082 G-A (rs1256049) in pre- or
postmenopausal women if they received estrogen. In our
tamoxifen cohort, we found a statistically significant
association between ER-b (ESR2-02) and the triglyceride
change after 4 months of treatment in pre- and postmeno-
pausal women.
The biochemical mechanisms underlying these associa-
tions are of interest, as XbaI is an intronic SNP in ER-a and
ESR2-02 is located in the 30 untranslated region of ER-b. It is
possible, as others have suggested, that SNPs that do not
cause amino-acid change may alter gene expression, affect the
folding of mRNA, or be in linkage disequilibrium with a
functional site.2,30 Moreover, the role of polymorphisms in
genes that code for the coregulator proteins of the ERs and
that may alter their binding to ligands such as tamoxifen is
not clear. Other investigators have shown that tamoxifen
interferes with synthesis of cholesterol in hepatic cells by
inhibition of the conversion of precursor lipids31 and that
tamoxifen is a potent inhibitor of sterol D8-isomerase, a
cholesterol synthetic enzyme.32 Although our data suggest
that the mechanism of tamoxifen’s lipid-lowering effect may
be mediated by ERs, it is not known if these receptors
influence D-isomerase activity, or whether other downstream
signaling mechanisms are involved. These remain important
subjects for future research.
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The clinical significance of our findings may be sub-
stantial, as cardiovascular disease is the leading cause of death
in both men and women, and many women with breast
cancer now live more than 10 years after treatment. Recent
data suggest that lower lipid concentrations are associated
with better coronary heart outcomes compared with
previously accepted practice standards.33 However, two
recently reported prospective studies, the Women’s Health
Initiative1 and the Heart and Estrogen/Progesterone Replace-
ment Study,34 have provided data that challenge the widely
held belief in a cardioprotective role for estrogens. Contrary
to results regarding estrogen administration, most, but not all
studies of tamoxifen, have shown a positive cardioprotective
effect, and none have shown a deleterious effect.4,35,36 It is of
note that a large study on the effects of another selective ER
modulator, raloxifene,37 on cardiovascular outcomes showed
no effect, further illustrating the complexity of the interaction
between ER-active agents and overall cardiovascular effects.
This complexity emphasizes the value of future research in
this area as do a number of limitations of this study. These
include the absence of data on hormone concentrations in
these women that would allow more careful mechanistic
determinations of relationships between estrogen, androgen,
and progesterone concentration and effect, and the absence
of data on breast cancer or cardiovascular outcomes that are
not possible in a study of 1-year duration.
These data may also be relevant in the choice between
tamoxifen and aromatase inhibitors in postmenopausal
women being treated for breast cancer. Recently, several
studies have suggested a modest advantage in reduction of
breast cancer-related events for aromatase inhibitors versus
tamoxifen.38–42 Of concern, a small excess of coronary artery
events has been a worrisome, although not universal, finding
in the adjuvant trials of aromatase inhibitors versus
tamoxifen. As these agents are purely anti-estrogenic and
are associated with less beneficial lipid profiles compared
with tamoxifen,43 it might be advantageous to identify
individuals, based on ER genotypes, who are more likely to
experience overall global positive effects with one class of
drugs versus the other.
We conclude that ER genotypes are associated with
changes in serum lipid concentrations in breast cancer
patients receiving adjuvant tamoxifen treatment. These
changes were importantly affected by menopausal status.
Functional studies of polymorphism in the ERs are needed to
elucidate the biologic mechanisms that these data point to.
These findings require replication in other cohorts treated
with tamoxifen and, if validated, the genetic testing of ER
variants findings may play a role in the prediction of women
who will experience optimal changes in serum cholesterol
and its subfractions during tamoxifen therapy.
METHODS
Subjects and study design. Subjects in this study are part of a
prospective, multi-institutional observational open-label clinical
registry for which women 18 years and older who were initiating
treatment with tamoxifen were eligible. The study design has already
been described in detail and is listed on http://www.clinicaltrials.gov
(the trial identifier is NCT00228930).24 Participants were enrolled if
they had newly diagnosed, non-metastatic breast cancer or if they
were at high risk for developing breast cancer and about to start
tamoxifen. Patients were recruited to the cohort from the breast
cancer clinics at the University of Michigan Comprehensive Cancer
Center and the Lombardi Comprehensive Cancer Center at
Georgetown University. Patients enrolled at the Indiana University
School of Medicine site did not have serum samples collected for
conventional analysis of cholesterol, LDL, HDL, and triglycerides,
but were part of a separate study designed to examine the effects of
tamoxifen on lipid subfractions.
All enrollees had to have completed all appropriate primary
surgery, radiation, and adjuvant chemotherapy. Pretreatment
medical histories, medication lists, physical examinations, and
laboratory samples were obtained for each subject at baseline and
4, 8, and 12 months after the start of tamoxifen treatment. Patients
were excluded from enrollment for the following reasons: if they had
been given tamoxifen concurrently with adjuvant chemotherapy or
if they were taking other adjuvant endocrine therapies; if they were
pregnant or lactating; or if they were on chronic corticosteroid or
megestrol acetate therapies. The Institutional Review Board at each
study site approved the study, and all subjects gave their written
informed consent.
This study describes the results of the substudy of associations
between candidate genetic polymorphisms in ER-a, ER-b, and
CYP2D6 and tamoxifen-induced lipid changes. Overall, 290 patients
were enrolled into the registry from April 2001 to January 2006. Of
these, 176 patients had completed 4 months of tamoxifen and had
baseline and serial lipid levels that were appropriately collected and
processed at the University of Michigan and Georgetown University.
Patients enrolled into the registry from Indiana University were not
included in these analyses of lipid concentrations. Therefore, this
study includes 176 subjects who were enrolled at the University of
Michigan and Georgetown University, and who had completed
sufficient follow-up with appropriate specimen collection to be
evaluable.
Participants were classified as either premenopausal, perimeno-
pausal, or postmenopausal based on history. Women were classified
as premenopausal if they were having regular menstrual periods.
They were classified as postmenopausal if they had been amenor-
rheic for 12 consecutive months, had undergone bilateral oophor-
ectomy, or had undergone hysterectomy without bilateral
oophorectomy and were older than 60 years. Perimenopausal
women were those who did not fit either category.
Patients who were recorded as taking medications known to alter
lipid profiles, other than tamoxifen, were accrued into the primary
cohort of 176 subjects for the lipid substudy, provided that there was
no change in the dose of the lipid-altering medication during the
study. The 176 subjects were included in the analysis of baseline lipid
concentration and change from baseline to 4 months independent
of genotype analysis. To minimize the confounding effects of lipid-
altering medications on the analyses of genotype association with
lipid level changes, women who changed therapy with such
medications were excluded from the study and women taking stable
doses of antilipidemic drugs (22 subjects) were excluded from our
assessment of the effects of tamoxifen on serum lipid concentrations
overall, and from the specific analysis of genetic associations as a
result. In addition, women classified as perimenopausal (20
subjects), for whom menstrual status and ovarian function are
uncertain, were excluded from the genotype–phenotype analyses,
reducing the number of subjects for the genotype association
analyses to 134 patients.
Sample collection. Ten milliliters of blood was collected at baseline
in heparinized vacutainer tubes (Becton-Dickinson, Franklin Lakes,
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NJ) and separated for genotyping and collection of plasma. At each
follow-up visit, blood (5ml) was collected in heparinized containers
and plasma was separated within 60min by centrifugation at 2,060 g.
Venous blood samples for lipid analysis were collected after an
overnight fast immediately before and after 4 months of tamoxifen
therapy. All blood samples (whole blood and plasma) were shipped
in cryogenic vials (Corning, Cambridge, MA) to the Division of
Clinical Pharmacology at Indiana University and were stored at
801C until analyses were performed.
Genotyping. Candidate genes: On the basis of previous studies by
our group and others, we chose to conduct analyses of serum lipid
concentrations at baseline and after 4 months of tamoxifen and to
correlate these concentrations with genetic variants in three
candidate genes: ERa (ESR1), ERb (ESR2), and CYP2D6. We
specifically looked at the following SNPs: ESR1_PvuII, ESR1_XbaI,
ESR2_01, ESR2_02, and CYP2D6 *1, *4, and *6. Genotyping data
can be found on the Pharmacogenetics and Pharmacogenomics
Knowledge Base website (http://www.pharmgkb.org) with accession
IDs CYP2D6 (PS204849, PS204850, PS204858, PS204859, PS204873,
PS204874, PS204875, PS204901, PS204991, and PS204996), ESR1
(PS204992 and PS204997), and ESR2 (PS205000 and PS203537,
PS203538 and PS204999).
Sequencing: Genomic DNA was extracted from whole blood
samples using the QIAamp midi kit (Qiagen, Valencia, CA). ER-a
genotype was determined using the method described by Herrington
et al.2 with minor modifications. Genomic DNA was amplified using
the primers CTGCCACCCTATCTGTATCTTTTCCTATTCTCC (for-
ward) and TCTTTCTCTGCC ACCCTGGCGTCGATTATCTGA
(reverse) at final concentrations of 200nM. Genotyping for two
ER-b SNPs (ESR2-01: rs#1256049; ESR2-02: rs#4986938) was
performed by TaqMan assays as described previously by the
National Cancer Institute’s Cancer Genome Anatomy Project
(CGAP) (http://cgap.nci.nih.gov/). The ESR2-01 primers were
TTTGTGGAGCTCAGCCTGTTC (forward) and CATCATTAA
CACCTCCATCCAACA (reverse), and the probes were FAM-
CAAGTGCGGCTCT-MGB and VIC-ACCAAGTACGGCTCT-MGB.
The ESR2-02 primers were CCTGGCCCTGAGGTGAACT (forward)
and GCCCAGGCTCCTGACACA (reverse), and the probes were
FAM-AGGTCACAGGCTGAA-MGB and VIC-TCACAAGCT
GAAGCG-MGB. Screening for CYP2D6 alleles *1, *4, and *6 was
performed by endonuclease-specific mutation analysis, using a
4.7-kb fragment containing all nine exons that was amplified from
the genomic DNA using an expanded long-template polymerase
chain reaction, and this was used as a template to determine specific
genetic variants, as described previously.44,45 In addition, we used
the AmpliChip CYP450 Test to test for 33 CYP2D6 alleles (i.e., *1 to
*10AB, *11, *14A, *14B, *15, *17, *19, *20, *25, *26, *29 to *31, *35,
*36, *40, *41, *1xN, *2xN, *4xN, *10xN, *17xN, *35xN, and *41xN).
The AmpliChip CYP450 Test microarray contains more than 15,000
different oligonucleotide probes, which can be used to analyze both
sense and antisense strands of an amplified target DNA sample.
Measurement of serum lipids. Triglycerides, total cholesterol, and
HDL-cholesterol were analyzed at the clinical laboratories at
Georgetown University Medical Center and the University of
Michigan Health System using standard methods. All test centers
met the Clinical Laboratory Improvement Amendments (CLIA)
standards. LDL-cholesterol was calculated using the Friedewald
equation.46,47 Lipid data set can be found on http://www.pharmgk-
b.org with the following accession ID: PS206340. Lipid subfraction
measurements were performed at Children’s Hospital Oakland
Research Institute (Oakland, CA). Levels of LDL, intermediate-
density lipoprotein, and lipoprotein(a) peak particle size of the whole
plasma were determined using non-denaturing 2–14% polyacryla-
mide gradient gel electrophoresis, as described previously.48
Statistical analysis. In univariate analysis, means and SD were
calculated for all continuous variables, and frequencies for
categorical variables are reported. The Hardy–Weinberg equilibrium
tests were reported for each genotype. A repeated measure two-way
ANOVA model (time/menopause) with interaction was implemen-
ted to compare each baseline lipid to its month 4 level among
different menopause groups. Its analyses are reported in Table 2. A
two-way ANOVA (menopause/genotype) model with interaction
was implemented to analyze either a baseline lipid or a lipid change
from baseline to the fourth month. These analyses are reported in
Table 3a and b and Figures 2 and 3 . Three genetic associations were
tested: dominant, recessive, and gene–dose effect. The genotypic
association analyses were carried out on the 134 subjects who were
neither perimenopausal nor were taking concomitant lipid-lowering
medications. A bootstrap resampling algorithm was employed to
adjust for the assumptions of non-normality and unequal variance,
and this takes into account the correlations between the predictors
(genotypic and clinical).49 The family-wise type I error was
controlled for each phenotype (lipid), by generating empirical
distributions of the t-statistic using a bootstrap approach (i.e., by
randomly permuting the phenotype). It considered multiple tests
among SNPs and menopause strata. P-values of less than 5% were
considered to be statistically significant. The bootstrap resampling
algorithm was implemented using SAS (version 3.2.2, SAS Institute
Inc., 100 SAS Campus Dr, Cary, NC 27513), and the P-values were
calculated from 50,000 sets of bootstrap samples.
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